natgillin/translations-raw huggingface dataset:
If you have missed an injection, or injected too little, contact your doctor as soon as possible. 
Če ste izpustili injekcijo ali ste injicirali premalo, se čim prej posvetujte z zdravnikom.
Pack sizes of 1, 3, 5 or 10 pre-filled syringes. 
Velikosti pakiranj so 1, 3, 5 ali 10 napolnjenih injekcijskih brizg.
Insert the needle into the skin fold with a quick, firm action. 
Iglo v kožo zabodite hitro in odločno.
The data in the tables below describe adverse reactions reported from clinical trials and spontaneous reporting. 
Podatki v spodnjih razpredelnicah opisujejo neželene učinke, o katerih so poročali iz kliničnih preskušanj in spontanega poročanja.
• inflammation of the aorta (the large blood vessel which transports blood from the heart to the body), see section 2. 
• vnetje aorte (velike žile, ki prenaša kri od srca po telesu), glejte poglavje 2
If you experience a loss of response or failure to maintain a response with filgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise filgrastim's activity. 
Če opazite prenehanje odzivanja ali neuspešno ohranjanje odziva na filgrastim, bo zdravnik raziskal razloge za to, vključno s pojavom protiteles, ki nevtralizirajo delovanje filgrastima.
(Sweets syndrome) 
(Sweetov sindrom)
No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (> 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients. 
Splošnih razlik v varnosti ali učinkovitosti pri osebah, starejših od 65 let, v primerjavi z mlajšimi odraslimi (> 18 let starosti) osebami, ki so prejemale citotoksično kemoterapijo, niso opazili, klinične izkušnje pa niso pokazale razlik v odzivu med starejšimi in mlajšimi odraslimi bolniki.
Rates of generation of antibodies against filgrastim is generally low. 
Stopnje nastajanja protiteles proti filgrastimu so običajno nizke.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če ni uporabljeno takoj, je za čas shranjevanja med uporabo in razmere pred uporabo odgovoren uporabnik, Ta čas pa običajno ne sme presegati 24 ur pri temperaturi od 2 °C do 8 °C, razen če je razredčenje opravljeno v nadzorovanih in preverjenih (validiranih) aseptičnih razmerah.
Syringes are embossed with graduation rings in order to enable partial use if required. 
Injekcijske brizge imajo vtisnjene merilne obročke, ki omogočajo delno uporabo, če je to potrebno.
• plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever 
• boleče izbočene rane vijolične barve na okončinah in včasih na obrazu in vratu z vročino
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established. 
Varnost in učinkovitost uporabe filgrastima pri bolnikih z na novo nastalo akutno mieloično levkemijo, ki so mlajši od 55 let in imajo dobro citogenetiko [t(8;21), t(15;17) in inv(16)], nista bili dokazani.
Statistical analysis of the relationship between the number of CD34+ cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship. 
Statistična analiza razmerja med številom ponovno infundiranih celic CD34+ in hitrostjo obnove trombocitov po kemoterapiji v velikih odmerkih kaže zapleteno, vendar stalno medsebojno povezavo.
In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file. 
Za izboljšanje sledljivosti granulocitne kolonije spodbujajočih faktorjev (G-CSFs) mora biti dajanje zdravila Filgrastim HEXAL jasno zabeležno v zdravstveni kartoteki bolnika.
Use each syringe only for one injection. 
Vsako brizgo uporabite le za eno injiciranje.
• lungs do not function as they should, causing breathlessness (respiratory failure) 
• pljuča ne delujejo, kot bi morala, kar povzroča zasoplost (dihalna odpoved)
In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. 
V nekaterih primerih so se simptomi ob ponovni izpostavitvi zdravilu ponovili, kar nakazuje vzročno povezavo.
Filgrastim HEXAL is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). 
Zdravilo Filgrastim HEXAL se običajno daje kot vsakodnevna injekcija v tkivo tik pod kožo (kar se imenuje podkožna injekcija).
It can also be given as a daily slow injection into the vein (known as an intravenous infusion). 
Daje se lahko tudi v obliki počasne injekcije v žilo (kar se imenuje intravenska infuzija).
1995 - 2000b a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period 
1995 - 2000b a Analiza obsega študije, ki vključujejo presaditve kostnega mozga v tem časovnem obdobju; v nekaterih študijah je bila uporabljena GM-CSF
If you are not sure about giving the injection or you have any questions, please ask your doctor or nurse for help. 
Če ste negotovi glede dajanja injekcije ali pa imate kakršna koli vprašanja, prosite za pomoč svojega zdravnika ali medicinsko sestro.
Each graduation ring corresponds to a volume of 0.1 ml. 
Vsak merilni obroček ustreza volumnu 0,1 ml.
How is Filgrastim HEXAL given and how much should I take? 
Kako se daje zdravilo Filgrastim HEXAL in koliko ga naj vzamem?
When diluted in glucose 50 mg/ml (5%) solution, filgrastim is compatible with glass and a variety of plastics including polyvinylchloride, polyolefin (a copolymer of polypropylene and polyethylene) and polypropylene. 
Če je razredčen s 5 % (50 mg/ml) raztopino glukoze, je filgrastim kompatibilen s steklom in različnimi plastičnimi materiali, vključno s PVC, poliolefinom (kopolimerom polipropilena in polietilena) in polipropilenom.
Haematuria was common and proteinuria occurred in a small number of patients. 
Hematurija je bila pogosta, pri majhnem številu bolnikov pa se je pojavila proteinurija.
Effects of filgrastim on prenatal development have been studied in rats and rabbits. 
Učinki filgrastima na prenatalni razvoj so bili preučeni pri podganah in kuncih.
The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. 
Varnost in učinkovitost filgrastima, uporabljenega na isti dan kot je bila uporabljena mielosupresivna citotoksična kemoterapija, nista bili dokončno potrjeni.
As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. 
Tako kot drugi hematopoetski rastni faktorji tudi G-CSF in vitro spodbuja človeške endotelijske celice.
The recommendation of a minimum yield of ≥ 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution. 
Najmanjši priporočeni delež ≥ 2,0 x 106 CD34+ celic/kg temelji na objavljenih podatkih, po katerih je to število zadostovalo za hematološko obnovo.
Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-fluorouracil indicates that the severity of neutropenia may be exacerbated. 
Preliminarni podatki, dobljeni pri manjšem številu bolnikov, ki so se sočasno zdravili s filgrastimom in 5-fluorouracilom, kažejo, da se stopnja izraženosti nevtropenije lahko še poveča.
In most cases aortitis was diagnosed by CT scan and generally resolved after withdrawal of G-CSF. 
Aortitis so v večini primerov diagnosticirali s slikanjem s CT, na splošno pa je minil po ukinitvi G
• if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria). 
• če se zdravite zaradi hude kronične nevtropenije in imate kri v urinu (hematurija).
If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome [MDS]). 
Če ste bolnik s hudo kronično nevtropenijo, obstaja tveganje, da se pri vas razvije krvni rak (levkemija, mielodisplastični sindrom [MDS]).
Then, if ANC remains > 1.0 x 109/l for 3 more consecutive days 
Nato, če ANC ostane > 1,0 x 109/l še v obdobju naslednjih treh zaporednih dni
In patients with severe chronic neutropenia (SCN) 
Pri bolnikih s hudo kronično nevtropenijo (SCN - Severe Chronic Neutropenia)
In clinical trials in cancer patients musculoskeletal pain was mild or moderate in 10%, and severe in 3% of patients. 
V kliničnih preskušanjih pri bolnikih z rakom je bila mišično-skeletna bolečina blaga do zmerna pri 10 % bolnikov in huda pri 3 % bolnikov.
The effects of filgrastim overdosage have not been established. 
Učinki prevelikega odmerjanja filgrastima niso bili ugotovljeni.
These could be symptoms of a condition called “sepsis” (also called "blood poisoning"), a severe infection with whole-body inflammatory response which can be life threatening and needs urgent medical attention. 
To so lahko simptomi stanja, imenovanega "sepsa" (ali "zastrupitev krvi"), hude okužbe z vnetnim odzivom celotnega telesa, ki je lahko smrtno nevarna in zahteva nujno zdravniško pomoč.
Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Filgrastim HEXAL was comparable to that of the reference product after subcutaneous and intravenous administration. 
Randomizirana, dvojno slepa, po enkratnem in večkratnem odmerku, navzkrižna študija na 204 zdravih prostovoljcih kaže, da je farmakokinetični profil zdravila Filgrastim HEXAL primerljiv s farmakokinetičnim profilom referenčnega zdravila po subkutani in intravenski uporabi.
The mobilisation and apheresis procedures should be performed in collaboration with an oncologyhaematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed. 
Postopki izplavljanja (mobilizacije) in afereze se morajo izvajati v sodelovanju z onkološkim-hematološkim središčem, ki ima sprejemljive izkušnje na tem področju, in kjer je mogoče neoporečno izvajati spremljanje hematopoetskih matičnih celic.
Risks associated with increased doses of chemotherapy 
Tveganja, povezana z velikimi odmerki kemoterapije
Absolute neutrophil count (ANC) should be monitored closely, especially during the first few weeks of filgrastim therapy. 
Absolutno število nevtrofilcev (ANC) je treba skrbno spremljati, zlasti v obdobju prvih nekaj tednov zdravljenja s filgrastimom.
Filgrastim therapy should only be given in collaboration with an oncology centre which has experience in G-CSF treatment and haematology and has the necessary diagnostic facilities. 
Zdravljenje s filgrastimom se lahko izvaja le v sodelovanju z onkološkim središčem, ki ima izkušnje z zdravljenjem z G-CSF in izkušnje v hematologiji, in razpolaga s potrebnimi diagnostičnimi zmogljivostmi.
Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim or pegfilgrastim. 
Na splošno so dogodki glomerulonefritisa izzveneli z zmanjšanjem odmerka ali prenehanjem uporabe filgrastima ali pegfilgrastima.
Filgrastim HEXAL is provided with or without a needle safety guard and you will be shown how to use this by your doctor or nurse. 
Zdravilo Filgrastim HEXAL je opremljeno z zaščito za iglo ali pa je brez nje, vaš zdravnik ali medicinska sestra pa vam bosta pokazala, kako to uporabljati.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Filgrastim HEXAL therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Filgrastim HEXAL, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight. 
Z levkaferezo je treba začeti peti dan in jo, če je potrebno, nadaljevati do šestega dne, da se zbere 4 x 106 celic CD34+/kg prejemnikove telesne mase.
Do not use this medicine if you notice discolouration, cloudiness or particles, it should be a clear, colourless to slightly yellowish liquid. 
Ne uporabljajte tega zdravila, če opazite obarvanje, motnost ali delce, saj mora biti tekočina bistra in brezbarvna do rahlo rumenkasta.
The efficacy of treatment was clear for this age-group, which included most patients with congenital neutropenia. 
Učinkovitost zdravljenja v tej starostni skupini, v katero so bili vključeni večinoma bolniki s prirojeno nevtropenijo, je bila nedvoumna.
If partial use of a syringe is required, remove unwanted solution before injection. 
Če je treba uporabiti le del vsebine injekcijske brizge, pred injiciranjem odstranite neželeno raztopino.
- The active substance is filgrastim. 
- Učinkovina je filgrastim.
Subsequently the dose may be individually adjusted every 1 - 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l. 
Nato je mogoče odmerek individualno prilagajati na vsak(a) 1 do 2 tedna, da se ohrani povprečno število nevtrofilcev med 1,5 x 109/l in 10 x 109/l.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 72 hours (but not above 25°C). 
Brizgo lahko vzamete iz hladilnika in jo pustite na sobni temperaturi enkrat za največ 72 ur (pri temperaturi do 25 °C).
In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 µg/kg/day. 
Pri brejih podganah niso ugotovili toksičnih učinkov na samico ali plod pri odmerkih do 575 µg/kg/dan.
Filgrastim should be discontinued and appropriate treatment given in these cases. 
V takšnih primerih je treba z dajanjem filgrastima prenehati in uporabiti ustrezno zdravljenje.
The safety and efficacy in neonates and patients with autoimmune neutropenia have not been established. 
Varnost in učinkovitost pri novorojenčkih in bolnikih z avtoimunsko nevtropenijo nista bili ugotovljeni.
Inject the Filgrastim HEXAL solution as you have been shown by your doctor. 
Raztopino zdravila Filgrastim HEXAL injicirajte tako, kot vam je pokazal zdravnik.
Store in a refrigerator (2°C - 8°C). 
Shranjujte v hladilniku (pri temperaturi od 2 °C - 8 °C).
The incidence of fever and documented infections were not reduced in either setting. 
Pogostnost pojavljanja zvišane telesne temperature in dokumentiranih okužb se v nobenem od teh primerov nista zmanjšali.
Among these, two cases of platelets < 50 x 109/l were reported and attributed to the leukapheresis procedure. 
Med temi so v dveh primerih poročali o številu trombocitov < 50 x 109/l, kar so pripisovali postopku levkafereze.
In randomised clinical trials, a subcutaneous dose of 230 μg/m2/day (4.0 to 8.4 μg/kg/day) was used. 
V randomiziranih kliničnih preskušanjih so uporabljali subkutani odmerek 230 µg/m2/dan (4,0 do 8,4 µg/kg/dan).
- Treatment of persistent neutropenia (ANC ≤ 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. 
- Zdravljenje trdovratne nevtropenije (absolutno število nevtrofilcev ≤ 1,0 x 109/l) pri bolnikih z napredovalo okužbo s HIV, da bi zmanjšali tveganje za pojav bakterijskih okužb, kadar drugi načini obvladovanja nevtropenije niso primerni.
Use of filgrastim in patients with HIV infection maintains normal neutrophil counts to allow scheduled dosing of antiviral and/or other myelosuppressive medication. 
Uporaba filgrastima pri bolnikih, okuženih s HIV vzdržuje normalno število nevtrofilcev, kar omogoča načrtovano odmerjanje protivirusnih in/ali drugih mielosupresivnih zdravil.
Filgrastim HEXAL can be used: 
Zdravilo Filgrastim HEXAL se lahko uporablja:
In view of limited safety and efficacy data in patients with secondary acute myelogenous leukaemia (AML), filgrastim should be administered with caution. 
Glede na to, da je podatkov o varnosti in učinkovitosti pri bolnikih s sekundarno akutno mieloično levkemijo (AML) malo, je treba filgrastim uporabljati previdno.
For patients treated with filgrastim diluted to concentrations < 1.5 MU/ml (15 μg/ml), human serum albumin (HSA) should be added to a final concentration of 2 mg/ml. 
Pri bolnikih, ki se zdravijo s filgrastimom, razredčenim na koncentracije pod 1,5 M e./ml (15 µg/ml), je treba dodati humani serumski albumin (HSA) do končne koncentracije 2 mg/ml.
The mechanism of vasculitis in patients receiving filgrastim is unknown. 
Mehanizem vaskulitisa pri bolnikih, ki prejemajo filgrastim, ni znan.
While maintaining pressure on the plunger, remove the syringe from the patient. 
Medtem ko še vedno vzdržujete pritisk na bat odstranite iglo iz bolnika.
A common side effect of filgrastim use is pain in your muscles or bones (musculoskeletal pain), which can be helped by taking standard pain relief medicines (analgesics). 
Pogost neželeni učinek uporabe filgrastima je bolečina v mišicah ali kosteh (mišično-skeletna bolečina), pri kateri pomagajo standardna zdravila za lajšanje bolečin (analgetiki).
Filgrastim HEXAL is available in packs containing 1, 3, 5 or 10 pre-filled syringes with injection needle and with or without a needle safety guard. 
Zdravilo Filgrastim HEXAL je na razpolago v pakiranjih, ki vsebujejo 1, 3, 5 ali 10 napolnjenih injekcijskih brizg z injekcijsko iglo, z varnostno zaščito za iglo, ali brez te zaščite.
- have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing as these could be signs of a severe allergic reaction (hypersensitivity). 
- se nenadoma pojavijo znaki alergije, kot so izpuščaj, srbenje ali koprivnica na koži, otekanje obraza, ustnic, jezika ali drugih delov telesa, zasoplost, piskanje v pljučih ali oteženo dihanje, ker so to lahko znaki hude alergijske reakcije (preobčutljivost).
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day). 
Mladiči podgan, ki so prejemale filgrastim v perinatalnem obdobju in obdobju laktacije, so imeli zakasnjeno zunanjo diferenciacijo in zastoj rasti (≥ 20 µg/kg/dan) ter nekoliko manjšo stopnjo preživetja (100 µg/kg/dan).
Common (≥ 1/100 to 
(≥1/100 do
Uncommon (≥ 1/1,000 to 
Občasni (≥1/1.000 do
If you develop or are likely to develop cancers of the blood, you should not use Filgrastim HEXAL unless instructed by your doctor. 
Če se krvni rak razvije ali če obstaja verjetnost, da se bo razvil, zdravila Filgrastim HEXAL ne smete uporabljati, razen če vam je tako naročil zdravnik.
In some SCN patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. 
Pri nekaterih bolnikih s hudo kronično nevtropenijo (SCN) lahko filgrastim nekoliko poveča tudi število eozinofilcev in bazofilcev v obtoku v primerjavi z izhodiščno vrednostjo; nekateri izmed teh bolnikov imajo lahko eozinofilijo ali bazofilijo že pred zdravljenjem.
Cases of capillary leak syndrome have been reported with granulocyte colony-stimulating factor use. 
Poročali so o primerih sindroma kapilarne prepustnosti med uporabo granulocitne kolonije spodbujajočega faktorja.
Filgrastim is not indicated for use in these conditions. 
Uporaba filgrastima pri teh stanjih ni indicirana.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. 
Po razredčitvi: Kemična in fizikalna stabilnost razredčene raztopine za infundiranje med uporabo sta bili dokazani za obdobje 24 ur pri temperaturi od 2 °C do 8 °C.
Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present. 
Kot se pričakuje pri vseh bioloških zdravilih, do nastanka vezavnih protiteles pride, vendar ta protitelesa niso bila povezana z nevtralizacijsko aktivnostjo.
What you need to know before you use Filgrastim HEXAL Do not use Filgrastim HEXAL 
Kaj morate vedeti, preden boste uporabili zdravilo Filgrastim HEXAL Ne uporabljajte zdravila Filgrastim HEXAL
White blood cell counts of 100 x 109/l or greater have been observed in less than 5% of cancer patients receiving filgrastim at doses above 0.3 MU/kg/day (3 μg/kg/day). 
Število belih krvničk 100 x 109/l ali več so ugotovili pri manj kot 5 % bolnikov z rakom, ki so dobivali filgrastim v odmerkih nad 0,3 M e./kg/dan (3 µg/kg/dan).
In clinical studies, > 90% of patients responded at these doses, achieving reversal of neutropenia in a median of 2 days. 
V kliničnih študijah se je na te odmerke odzvalo > 90 % bolnikov, mediana vrednosti časa, po katerem je bila nevtropenija odpravljena, pa je znašala dva dneva.
In view of the possible risk of microbial contamination, Filgrastim HEXAL syringes are for single use only. 
Zaradi možnega tveganja kontaminacije z mikrobi so brizge zdravila Filgrastim HEXAL namenjene le enkratni uporabi.
Urinalysis monitoring is recommended. 
Priporoča se spremljanje z analiziranjem urina.
For maintaining normal neutrophil counts 
Za vzdrževanje normalnega števila nevtrofilcev
• a change in how your body regulates fluids within your body and may result in puffiness (fluid volume disturbances) 
• sprememba načina, kako telo uravnava tekočine v telesu, kar lahko povzroči zabuhlost (motnje volumna tekočine)
These could be symptoms of a condition called “Capillary Leak Syndrome” which causes blood to leak from the small blood vessels into your body and needs urgent medical attention. 
To so lahko simptomi motnje, imenovane "sindrom kapilarne prepustnosti", ki povzroči puščanje krvi iz drobnih krvnih žilic v telesu, ki zahteva nujno zdravniško pomoč.
Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans. 
Povečana hematopoetska aktivnost kostnega mozga kot odgovor na zdravljenje z rastnim faktorjem je bila povezana s prehodnimi nenormalnimi slikami kosti.
• severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis) 
• hude bolečine v kosteh, prsnem košu, prebavilih ali sklepih (srpastocelična anemija s krizo)
The observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3 - 5 times the exposures observed in patients treated with the clinical dose. 
Odmerek z ugotovljenimi neželenimi učinki, povezanimi s toksičnimi učinki na zarodek oz. plod, je bil v tej študiji 10 µg/kg/dan, kar ustreza sistemski izpostavljenosti, ki je približno 3 - 5-krat večja od izpostavljenosti bolnikov, zdravljenih s kliničnim odmerkom.
Filgrastim dosing should be maintained until the last leukapheresis. 
Z dajanjem filgrastima je treba nadaljevati do zadnje levkafereze.
Filgrastim HEXAL is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of proteins called cytokines. 
Zdravilo Filgrastim HEXAL je rastni faktor za bele krvne celice (granulocitne kolonije spodbujajoči faktor) in sodi v skupino beljakovin, imenovanih citokini.
If more than one leukapheresis is required, particular attention should be paid to donors with platelets < 100 x 109/l prior to leukapheresis; in general apheresis should not be performed if platelets < 75 x 109/l. 
Če je potrebna več kot ena levkafereza, je treba posebno pozornost nameniti darovalcem, pri katerih število trombocitov pred levkaferezo znaša < 100 x 109/l; običajno se afereze ne sme narediti, če je število trombocitov < 75 x 109/l.
• if you experience kidney injury (glomerulonephritis). 
• če pride do poškodb ledvic (glomerulonefritis).